Editas Medicine (EDIT) investor relations material

Executive summary

• EDIT-401 is the lead candidate, targeting hyperlipidemia by upregulating LDLR expression, with preclinical data showing ~90% reduction in LDL-C, Lp(a), and ApoB in non-human primates; Phase 1/2 trial preparations are underway, with topline data expected in 2027.

• Clinical trial sites for EDIT-401 have been selected in Australia and New Zealand, with CTN submission and trial initiation for HeFH on track; data update anticipated in Q1 2027.

• Discontinued the reni-cel program and reduced workforce by 65% in late 2024, resulting in significant restructuring and impairment charges in 2025, but a restructuring benefit in 2026.

• Revenue is primarily from collaborations and licensing, notably with BMS and Vertex; no product revenue generated to date.

• Strengthened capital position through a $125M public offering, with potential for an additional $194.4M from warrant exercises.

Financial highlights

• Collaboration and R&D revenues rose to $11.9M for Q2 2026 (up $8.3M YoY), mainly from deferred revenue recognition related to BMS.

• Net loss for Q2 2026 was $18.2M ($0.15/share), a significant improvement from $53.2M ($0.63/share) in Q2 2025; net loss for the six months ended June 30, 2026 was $43.2M, down from $129.3M YoY.

• Operating expenses for Q2 2026 were $30.4M, down 45% YoY, reflecting lower restructuring and impairment charges.

• Cash, cash equivalents, and marketable securities totaled $211.6M as of June 30, 2026, up from $146.6M at year-end 2025.

• Research and development expenses increased to $20.2M, while G&A expenses decreased to $11.6M year-over-year.

Outlook and guidance

• Existing cash and equivalents expected to fund operations into the second half of 2028.

• Enrollment for the dose-finding portion of the Phase 1/2 EDIT-401 trial to be completed with topline data in 2027; data update anticipated in Q1 2027.

• Anticipates increased expenses as EDIT-401 advances into clinical trials and as preclinical pipeline development continues.

• No profitability expected for 2026 or the foreseeable future.